734 related articles for article (PubMed ID: 12121236)
21. The immunohistochemical profile of malignant mesotheliomas of the tunica vaginalis: a study of 20 cases.
Winstanley AM; Landon G; Berney D; Minhas S; Fisher C; Parkinson MC
Am J Surg Pathol; 2006 Jan; 30(1):1-6. PubMed ID: 16330935
[TBL] [Abstract][Full Text] [Related]
22. Expression of calretinin by breast carcinoma and the potential for misdiagnosis of mesothelioma.
Powell G; Roche H; Roche WR
Histopathology; 2011 Nov; 59(5):950-6. PubMed ID: 22092406
[TBL] [Abstract][Full Text] [Related]
23. Ten cases of feline mesothelioma: an immunohistochemical and ultrastructural study.
Bacci B; Morandi F; De Meo M; Marcato PS
J Comp Pathol; 2006 May; 134(4):347-54. PubMed ID: 16712862
[TBL] [Abstract][Full Text] [Related]
24. The value of 'mesothelium-associated' antibodies in distinguishing between metastatic renal cell carcinomas and mesotheliomas.
Osborn M; Pelling N; Walker MM; Fisher C; Nicholson AG
Histopathology; 2002 Oct; 41(4):301-7. PubMed ID: 12383211
[TBL] [Abstract][Full Text] [Related]
25. Synchronous diffuse malignant mesothelioma and carcinomas in asbestos-exposed individuals.
Attanoos RL; Thomas DH; Gibbs AR
Histopathology; 2003 Oct; 43(4):387-92. PubMed ID: 14511258
[TBL] [Abstract][Full Text] [Related]
26. The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell/pleomorphic (sarcomatoid) carcinomas of the lung: evidence-based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center.
Marchevsky AM; LeStang N; Hiroshima K; Pelosi G; Attanoos R; Churg A; Chirieac L; Dacic S; Husain A; Khoor A; Klebe S; Lantuejoul S; Roggli V; Vignaud JM; Weynard B; Sauter J; Henderson D; Nabeshima K; Galateau-Salle F
Hum Pathol; 2017 Sep; 67():160-168. PubMed ID: 28782639
[TBL] [Abstract][Full Text] [Related]
27. E-cadherin, N-cadherin, and calretinin in pleural effusions: the good, the bad, the worthless.
Simsir A; Fetsch P; Mehta D; Zakowski M; Abati A
Diagn Cytopathol; 1999 Mar; 20(3):125-30. PubMed ID: 10086235
[TBL] [Abstract][Full Text] [Related]
28. Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions.
Hanley KZ; Facik MS; Bourne PA; Yang Q; Spaulding BO; Bonfiglio TA; Xu H
Cancer; 2008 Feb; 114(1):49-56. PubMed ID: 18098206
[TBL] [Abstract][Full Text] [Related]
29. Spindle cell thymomas: an immunohistochemical study of 30 cases.
Weissferdt A; Hernandez JC; Kalhor N; Moran CA
Appl Immunohistochem Mol Morphol; 2011 Jul; 19(4):329-35. PubMed ID: 21386704
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic usefulness of endobronchial ultrasound-guided transbronchial needle aspiration in a case with malignant pleural mesothelioma.
Hamamoto J; Notsute D; Tokunaga K; Sasaki J; Kojima K; Saeki S; Tanaka R; Tanaka H; Kohrogi H
Intern Med; 2010; 49(5):423-6. PubMed ID: 20190476
[TBL] [Abstract][Full Text] [Related]
31. D2-40 and calretinin - a tissue microarray analysis of 341 malignant mesotheliomas with emphasis on sarcomatoid differentiation.
Hinterberger M; Reineke T; Storz M; Weder W; Vogt P; Moch H
Mod Pathol; 2007 Feb; 20(2):248-55. PubMed ID: 17361207
[TBL] [Abstract][Full Text] [Related]
32. Calretinin is essential for mesothelioma cell growth/survival in vitro: a potential new target for malignant mesothelioma therapy?
Blum W; Schwaller B
Int J Cancer; 2013 Nov; 133(9):2077-88. PubMed ID: 23595591
[TBL] [Abstract][Full Text] [Related]
33. Pleural mesothelioma: diagnostic problems and evaluation of prognostic factors.
Ismail HM; Nouh MA; Abulkheir IL; Abd El-Rahman Ael-R; Tawfik HN
J Egypt Natl Canc Inst; 2006 Dec; 18(4):303-10. PubMed ID: 18301454
[TBL] [Abstract][Full Text] [Related]
34. Spindle cell tumours of the pleura: a clinical, histological and comparative genomic hybridization analysis of 14 cases.
Knuuttila A; Jee KJ; Taskinen E; Wolff H; Knuutila S; Anttila S
Virchows Arch; 2006 Feb; 448(2):135-41. PubMed ID: 16170537
[TBL] [Abstract][Full Text] [Related]
35. My approach to the diagnosis of mesothelial lesions.
Butnor KJ
J Clin Pathol; 2006 Jun; 59(6):564-74. PubMed ID: 16731600
[TBL] [Abstract][Full Text] [Related]
36. Expression of mesothelial markers in malignant mesotheliomas: an immunohistochemical evaluation of 173 cases.
Soomro IN; Oliveira R; Ronan J; Chaudry ZR; Johnson J
J Pak Med Assoc; 2005 May; 55(5):205-9. PubMed ID: 15960287
[TBL] [Abstract][Full Text] [Related]
37. The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis.
Cury PM; Butcher DN; Corrin B; Nicholson AG
J Pathol; 1999 Oct; 189(2):251-7. PubMed ID: 10547583
[TBL] [Abstract][Full Text] [Related]
38. The diagnostic utility of immunohistochemistry in distinguishing between mesothelioma and renal cell carcinoma: a comparative study.
Ordóñez NG
Hum Pathol; 2004 Jun; 35(6):697-710. PubMed ID: 15188136
[TBL] [Abstract][Full Text] [Related]
39. Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma.
Brown RW; Clark GM; Tandon AK; Allred DC
Hum Pathol; 1993 Apr; 24(4):347-54. PubMed ID: 7684019
[TBL] [Abstract][Full Text] [Related]
40. [Clinical and pathologic features of extrapleural sarcomatoid mesothelioma].
Wei MC; Yang SJ
Zhonghua Bing Li Xue Za Zhi; 2017 Aug; 46(8):559-564. PubMed ID: 28810297
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
